An observational study in Chronic Obstructive Pulmonary Disease, sponsored by Fraunhofer-Institute of Toxicology and Experimental Medicine. Completed at 1 site in Germany. Per ClinicalTrials.gov, last updated 2025-02-25.
Sponsored by Fraunhofer-Institute of Toxicology and Experimental Medicine · Observational
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 539 studies in Pulmonary Disease, Chronic Obstructive with a site in Germany — 33 open to participants now, 46 under way, 10 of them phase 3. Pulmonary Disease, Chronic Obstructive · Germany.
Among the 539 studies in Pulmonary Disease, Chronic Obstructive with a site in Germany, this one is the 59th largest by enrollment of the 96 observational ones that give a count, is one of 23 that started in 2015, is one of 97 observational ones, and was the 333rd registered.
5,529 studies on the registry are indexed under Pulmonary Disease, Chronic Obstructive; 858 are open to participants now.
Browse Pulmonary Disease, Chronic Obstructive studies →33 of the 539 studies in Pulmonary Disease, Chronic Obstructive with a site in Germany are open now. Recruiting first, the newest first:
Fraunhofer-Institute of Toxicology and Experimental Medicine · Sites in Germany
Ages 40+
Eli Lilly and Company · Sites in Germany, United States, Argentina and 15 more countries
Ages 40–75
Grifols Therapeutics LLC · Sites in Germany, United States, Denmark and 6 more countries
Ages 18–80
Pfizer · Sites in Germany, United States, Argentina and 15 more countries
Ages 35–80
AstraZeneca · Sites in Germany, United Kingdom
Ages 40–80
A study can be open while its sites in Germany have not opened yet or have stopped. Only those recruiting at a site in Germany →
Of the 560 Pulmonary Disease, Chronic Obstructive studies recruiting now, 307 (55%) set no upper age limit and 82 (15%) stop at 75 or younger; 30 take children under 18; 88 take healthy volunteers.
This study: all sexes · healthy volunteers too.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
539 studies; the count open now beside each. This study's row is marked.
A study in two phases is counted once above. Listed by phase, each with its combined phases: Phase 1 44 · Phase 2 103 · Phase 3 146 · Phase 4 51
First in 2000; this study’s year is marked. 23 started in 2015.
By drug class, each counting the studies that test any of its medicines:
This study's enrollment of 116 is below the median of 159 across 1,498 observational studies indexed under Pulmonary Disease, Chronic Obstructive.
Median enrollment 156 across the 441 interventional studies, 178 across the 96 observational. Of the 456 that completed or were terminated, 232 (51%) have results posted.
This tab as a report to print or save as PDF → With an account.
400 of 539 have an industry lead sponsor. The 10 most frequent:
Fraunhofer-Institute of Toxicology and Experimental Medicine is the lead sponsor of 38 studies on the registry; 3 are open to participants now.
Fraunhofer-Institute of Toxicology and Experimental Medicine has 7 studies filed under Pulmonary Disease, Chronic Obstructive — fewer than ten, so there is no comparison to draw.
15 of the studies in Pulmonary Disease, Chronic Obstructive with a site in Germany that are under way reach primary completion within a year, 2 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT05878769Phase 3Hoffmann-La RocheA Study to Evaluate the Long-Term Safety of Astegolimab in Participants With Chronic Obstructive Pulmonary Disease (COPD) | 2027-06-30 |
| NCT07555483Phase 3Grifols Therapeutics LLCA Non-inferiority Pharmacokinetic and Safety/Tolerability Study of Two Different Doses of Weekly SC Alpha1-PI 15% Compared With Corresponding Standard IV Alpha1-PI in Participants With Alpha1-Antitrypsin Deficiency (AATD) | 2027-09-30 |
| NCT07751705Fraunhofer-Institute of Toxicology and Experimental MedicineInduced Sputum Collection in COPD Patients With and Without a Vibroacoustic Device | 2026-12 |
| NCT06712563AstraZenecaPooled Analysis of Single-arm Studies of Budesonide/Glycopyrronium/Formoterol (BGF) in Routine Care Setting | 2026-12-14 |
| NCT06154837GlaxoSmithKlineA Study for GSK3862995B in Healthy Participants and Participants With Chronic Obstructive Pulmonary Disease | 2026-12-16 |
Add all 15 to your calendar (.ics) → With an account.
Among the 539 studies in Pulmonary Disease, Chronic Obstructive with a site in Germany, from their registry updates:
This tab as a report to print or save as PDF → With an account.
Between 2012 and 2014, a cohort of 90 COPD subjects of disease severity grades GOLD I-IV as well as 60 healthy control subjects (30 smokers and 30 non-smokers) have been examined regarding different clinical and blood/ sputum derived biomarkers at the investigators' research center. This observation study will follow-up/re-examine all available subjects regarding disease course and treatment changes after 3 years (+/-6 months) for the investigation of ncRNA/ transcriptome biomarkers for their potential to indicate disease progression. In addition, biobanking of respective biosamples for potential future COPD biomarker research will be conducted.
All 150 patients of study "11-03 Ribolution" will be contacted and re-invited for the current follow-up study as completely as possible
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.
Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.
Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.
Informed consent
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Corticosteroids (steroids)
Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.
Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Clinically significant
Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Lung volumes by pulmonary function testing
forced expiratory volume in 1 second
Time frame: after 3 years ± 6 months
The record gives a start of Aug 2015, a primary completion of Mar 2017 and a completion of Mar 2017. It does not say whether these dates are actual or estimated.
How these figures are worked out, and which studies are left out of them.
This study is completed, as verified in Feb 2025. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Pulmonary Disease, Chronic Obstructive →
Fraunhofer-Institute of Toxicology and Experimental Medicine